AFT Pharmaceuticals Limited (AFT.NZ)
- Previous Close
3.0700 - Open
3.0700 - Bid 3.0600 x 231100
- Ask 3.0900 x 478300
- Day's Range
3.0700 - 3.1100 - 52 Week Range
2.8400 - 3.9200 - Volume
31,153 - Avg. Volume
21,231 - Market Cap (intraday)
324.036M - Beta (5Y Monthly) 0.23
- PE Ratio (TTM)
30.90 - EPS (TTM)
0.1000 - Earnings Date May 20, 2024 - May 24, 2024
- Forward Dividend & Yield 0.01 (0.36%)
- Ex-Dividend Date Jun 16, 2023
- 1y Target Est
3.70
AFT Pharmaceuticals Limited, together with its subsidiaries, engages in the development and sale of pharmaceutical products in New Zealand, Australia, Asia, and internationally. It offers products for use in the areas of allergy, cold and flu, digestive health, eye care, first aid, nail care, oral care, pain management, skin care, and supplements, as well as other products. AFT Pharmaceuticals Limited was incorporated in 1997 and is headquartered in Auckland, New Zealand.
www.aftpharm.com100
Full Time Employees
March 31
Fiscal Year Ends
Sector
Recent News: AFT.NZ
Performance Overview: AFT.NZ
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: AFT.NZ
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: AFT.NZ
Valuation Measures
Market Cap
324.04M
Enterprise Value
354.49M
Trailing P/E
29.86
Forward P/E
16.98
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
1.87
Price/Book (mrq)
4.38
Enterprise Value/Revenue
2.05
Enterprise Value/EBITDA
16.92
Financial Highlights
Profitability and Income Statement
Profit Margin
6.26%
Return on Assets (ttm)
8.53%
Return on Equity (ttm)
16.51%
Revenue (ttm)
174.5M
Net Income Avi to Common (ttm)
10.92M
Diluted EPS (ttm)
0.1000
Balance Sheet and Cash Flow
Total Cash (mrq)
6.17M
Total Debt/Equity (mrq)
55.41%
Levered Free Cash Flow (ttm)
-667.75k
Research Analysis: AFT.NZ
Company Insights: AFT.NZ
AFT.NZ does not have Company Insights